Peled and colleagues, members of a stem cell biotech firm (Gamida Cell, Jerusalem, Israel), has claimed, in a patent, that GHK increases proliferation of stem cells, while GHK-Cu increases their progression into differentiated cells [ 40 ]
The injection vehicle is carefully selected to ensure compatibility with both active ingredients while maintaining appropriate pH, osmolality, and other physical characteristics necessary for subcutaneous administration
In fact, this regimen was already tested in metastatic breast cancer with encouraging results (Falanga et al., 1998)
staggered titration Cycle driver GI tolerance sets the pace Tirzepatide Loading 2.5 5 7.5 10 12.5 mg (every 4 weeks) Frequency Once weekly Maintenance 15 mg weekly Route SubQ Cagrilintide Loading Start Week 9: 0.25 0.5 1.0 1.7 mg Frequency Once weekly Maintenance 2.4 mg weekly Route SubQ Weekly Schedule Example (Maintenance Phase) Monday Tirzepatide 15 mg (one site) + Cagrilintide 2.4 mg (different site) Tuesday No injections Wednesday No injections Thursday No injections Friday No injections Saturday No injections Sunday No injections Both compounds are once weekly